Jump to content

Genomic Health

Edit links
From Wikipedia, the free encyclopedia
Genomic Health, Inc.
Company typeSubsidiary
IndustryGenomics
FoundedAugust 2000;23 years ago(2000-08),inRedwood City, California,U.S.
FounderRandy Scott
Defunct2019(2019)(Acquired by Exact Sciences)
SuccessorExact Sciences
HeadquartersRedwood City, California,U.S.
Key people
ProductsOncotype DX
Number of employees
863(2017)
Websitewww.genomichealth.comEdit this at Wikidata
Footnotes / references
[1][2][3]

Genomic Health, Inc.was a company focusing ongeneticresearch specifically incancerdetection, based out ofRedwood City, California.[2]The company was acquired by and merged withExact Sciences Corporationin 2019.

History[edit]

Genomic Health, Inc. was founded in 2000 by Randy Scott, who had previously founded and been CEO atIncyte.[4]He formed the company after a close friend was diagnosed with cancer and had the idea for treatment based on the specific genome of theirtumor.[5]

By 2003 Genomic Health had developed Oncotype DX, a genomic assay that quantified the likelihood ofbreast cancerrecurrence.[6]This development took the company over three years andUS$30,000,000 to complete and then had to convince skeptics at the time of the validity of genetic testing.[6]

In July 2005 Genomic Health filed for aninitial public offeringto sell up toUS$75,000,000 in common stock. Investors at the time already includedVersant VenturesandKleiner Perkins Caufield & Byers.[7]On September 29, 2005(2005-09-29)it was listed on theNASDAQwith the symbol GHDX with the initial share price ofUS$12 for 5016722 shares.[8]

Genomic Health also started a subsidiary in 2010,Invitae,with the goal of aggregating multiple genetics tests. Invitae wasspun offin 2012.[9]

The company expanded with international headquarters inGenevaSwitzerland and UK headquarters inLondonin 2011.[10]

In July 2019,Exact Sciencesannounced that it was purchasing Genomic Health to increase the variety of medical tests they offer.[11]

See also[edit]

References[edit]

  1. ^"US SEC: Form 10-K Genomic Health, Inc".U.S. Securities and Exchange Commission.RetrievedApril 3,2018.
  2. ^ab"GENOMIC HEALTH, INC".OpenCorporates.13 December 2016.Retrieved10 January2017.
  3. ^Chaykowsk, Kathleen (10 April 2012)."CEO's dedication is behind Genomic Health's cancer tests".Peninsula Press.Retrieved10 January2017.
  4. ^Susan McKinnon; Sydel Silverman (1 June 2005).Complexities: Beyond Nature and Nurture.University of Chicago Press.p. 239.ISBN978-0-226-50024-9.Retrieved10 January2017.
  5. ^Cook, Kevin (7 October 2013)."Genomic Health Has Sickly Stock Chart".Forbes.Retrieved10 January2017.
  6. ^abChess, Robert; Denend, Lyn; Zenios, Stefanos (2006)."Genomic Health: Launching a Paradigm Shift... and an Innovative New Test".Stanford Graduate School of Business.Retrieved10 January2017.
  7. ^Simmers, Tim (19 July 2005)."Genomic Health files for an IPO".East Bay Times.Retrieved10 January2017.
  8. ^"GENOMIC HEALTH INC (GHDX) IPO".NASDAQ.Retrieved10 January2017.
  9. ^Lash, Alex (20 October 2015)."What's Your DNA Worth? The Scramble To Cash In On the Genome".exome.Retrieved10 January2017.
  10. ^"Company Timeline & Milestones".Genomic Health.Archived fromthe originalon 30 July 2019.Retrieved10 January2017.
  11. ^Flanagan, Cristin; Ahmed, Nabila (29 July 2019)."Exact Sciences to Buy Genomic Health for About $2.8 Billion".Bloomberg News.Retrieved30 July2019.

External links[edit]

  • Official websiteEdit this at Wikidata
  • Business data for Genomic Health, Inc.:
Retrieved from "https://en.wikipedia.org/w/index.php?title=Genomic_Health&oldid=1225627220"